Are off-target effects of imatinib the key to improving beta-cell function in diabetes?

The small tyrosine kinase (TK) inhibitor imatinib mesylate (Gleevec, STI571) protects against both type 1 and type 2 diabetes, but as it inhibits many TKs and other proteins, it is not clear by which mechanisms it acts. This present review will focus on the possibility that imatinib acts, at least i...

全面介绍

书目详细资料
主要作者: Nils Welsh
格式: 文件
语言:English
出版: Upsala Medical Society 2022-09-01
丛编:Upsala Journal of Medical Sciences
主题:
在线阅读:https://ujms.net/index.php/ujms/article/view/8841/14851